Citius Oncology grants director Smith 125K stock options

Available on EDGAR 11/13/2026 - 04:34 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:32 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Citius Oncology, Inc. (CTOR) director Robert Joseph Smith received a grant of 125,000 stock options on November 12, 2026, at an exercise price of $0.5223 per share. The options vest in full on November 12, 2027, subject to his Continuous Service to Citius Oncology or a Related Entity as of the vesting date, and expire November 12, 2036. No Rule 10b5-1 plan is reported.

The Form 4 also lists 125,000 earlier options exercisable at $1.0700 per share, expiring December 12, 2034, and 300,000 shares underlying restricted stock units granted September 19, 2025. The restricted stock units vest in full on September 19, 2028, subject to Continuous Service.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 1 txn

Insider Smith Robert Joseph

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F2	125,000	$0.00	$0.00
Holding	Stock Option (Right to Buy) F3	--	--	--
Holding	Common Stock F1	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 250,000 options, with 125,000 underlying shares of Common Stock (Direct); Common Stock — 300,000 shares (Direct)

Footnotes (3)

1. F1. Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
2. F2. These options were granted on November 12, 2026. The options vest in full on November 12, 2027, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
3. F3. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

Key Figures

New stock option grant: 125,000 options New option exercise price: $0.5223 per share New option expiration: November 12, 2036 +3 more

6 metrics

New stock option grant 125,000 options Granted November 12, 2026; vest in full November 12, 2027, subject to Continuous Service.

New option exercise price $0.5223 per share Options granted November 12, 2026.

New option expiration November 12, 2036 Expiration date for the 125,000 options granted November 12, 2026.

Earlier stock options 125,000 options Earlier options with a $1.0700 exercise price, expiring December 12, 2034.

Earlier option exercise price $1.0700 per share For the 125,000 earlier options.

Shares underlying restricted stock units 300,000 shares Restricted stock units granted September 19, 2025; vest in full September 19, 2028, subject to Continuous Service.

Key Terms

Stock Option (Right to Buy), restricted stock units, Continuous Service, Related Entity

4 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

restricted stock units financial

"Represents restricted stock units granted on September 19, 2025."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Continuous Service financial

"subject to the Reporting Person's Continuous Service"

Related Entity financial

"or a Related Entity (as defined in the award agreement)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When do CTOR director Robert Joseph Smith’s new stock options vest?

The 125,000 options granted to CTOR director Robert Joseph Smith on November 12, 2026, vest in full on November 12, 2027, subject to his Continuous Service to Citius Oncology or a Related Entity as of the vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Robert Joseph

(Last) (First) (Middle)

C/O CITIUS ONCOLOGY, INC.

11 COMMERCE DRIVE, 1ST FLOOR

(Street)

CRANFORD NEW JERSEY 07016

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CITIUS ONCOLOGY, INC. [ CTOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								300,000(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.5223	11/12/2026		A		125,000		(2)	11/12/2036	Common Stock	125,000	$0	125,000	D
Stock Option (Right to Buy)	$1.07							(3)	12/12/2034	Common Stock	125,000		125,000	D

Explanation of Responses:

1. Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

2. These options were granted on November 12, 2026. The options vest in full on November 12, 2027, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

3. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

	/s/ Alexander M. Donaldson, by Power of Attorney	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)